These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15504626)

  • 1. Optimization of opioid therapy for preventing incident pain associated with bone metastases.
    Mercadante S; Villari P; Ferrera P; Casuccio A
    J Pain Symptom Manage; 2004 Nov; 28(5):505-10. PubMed ID: 15504626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose.
    Mercadante S; Villari P; Ferrera P; Bianchi M; Casuccio A
    J Pain Symptom Manage; 2004 Apr; 27(4):352-9. PubMed ID: 15050663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid switching and burst ketamine to improve the opioid response in patients with movement-related pain due to bone metastases.
    Mercadante S; Villari P; Ferrera P; Arcuri E; David F
    Clin J Pain; 2009 Sep; 25(7):648-9. PubMed ID: 19692808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?
    Mercadante S; Villari P; Ferrera P; Casuccio A
    Eur J Pain; 2006 Feb; 10(2):153-9. PubMed ID: 16310719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
    Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S
    J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
    Mercadante S; Villari P; Ferrera P; Porzio G; Aielli F; Verna L; Casuccio A
    J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.
    Mercadante S; Villari P; Ferrera P; Mangione S; Casuccio A
    Clin J Pain; 2010 May; 26(4):306-9. PubMed ID: 20393265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.
    Mercadante S; Villari P; Ferrera P; Casuccio A; Mangione S; Intravaia G
    Br J Cancer; 2007 Jun; 96(12):1828-33. PubMed ID: 17519902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study.
    Mercadante S; Intravaia G; Villari P; Ferrera P; Riina S; Mangione S
    J Pain Symptom Manage; 2008 Mar; 35(3):307-13. PubMed ID: 18178368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
    Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
    Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids.
    Mercadante S; Intravaia G; Villari P; Ferrera P; Riina S; David F; Mangione S
    Clin J Pain; 2007; 23(9):793-8. PubMed ID: 18075407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of side effects of prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and/or antidepressant therapy in chronic non-cancer pain.
    Manchikanti L; Manchikanti KN; Pampati V; Cash KA
    Pain Physician; 2009; 12(1):259-67. PubMed ID: 19165308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion.
    Mercadante S; Villari P; Ferrera P; Casuccio A; Fulfaro F
    Cancer; 2002 Jul; 95(1):203-8. PubMed ID: 12115334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pain management of opioid-treated cancer patients in hospital settings in Denmark.
    Lundorff L; Peuckmann V; Sjøgren P
    Acta Anaesthesiol Scand; 2008 Jan; 52(1):137-42. PubMed ID: 18005379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.